The Motley Fool
22 Aug 2026, 11:30 UTC · 2h ago
Breakfast News: A Conversation With Ionis CEO
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
22 Aug 2026, 11:30 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The results of the HORIZON trial for Pelacarsen, which tests if lowering Lp(a) prevents heart attacks and strokes, are expected in the second half of 2026. — Clinical trial readouts for primary endpoints in major cardiovascular indicators are high-volatility catalysts for both Ionis and Novartis.
+0.60The biotech sector, tracked by the XBI ETF, is up 39% year-to-date in 2026, outperforming the technology sector. — Strong sector momentum suggests high risk appetite for biotech, though it indicates a potential crowded trade.
+0.30Which stocks this story touches
Mentioned as having a massive 177% single-day pop that lifted the entire biotech sector.
Continue reading
6 related stories
Top 2 movers · tap to explore
The ETF is up 39% year to date, beating the tech sector.
The article highlights its core technology, a conversation with the CEO regarding profitability milestones, and its ability to silence disease at the source.
Positive mention regarding the upcoming HORIZON trial for a licensed drug to prevent heart attacks and strokes.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
2h ago
